Aragen scales Renaissance Pharma’s cancer antibody to commercial GMP in just 9 months
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated